This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EDAP Receives South Korean FDA Approval For Sonolith I-move Lithotripter

LYON, France, Dec. 13, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today the approval of its new lithotripter Sonolith i-move by South-Korean Food and Drug Administration (KFDA).

South Korea is the second largest market in Asia for lithotripsy devices after Japan. This approval marks another milestone in EDAP's strategy to aggressively gain market share and reinforces the Company's 24-year presence in the South Korean market.   Through the 24 years, the Company has maintained its leading position as provider of high-end lithotripter devices. EDAP has one of the largest lithotripter installed base in South Korea, with more than 50 fully installed devices.

Mr. Y.H. Park, Managing Director of EDAP's direct and wholly owned representative office in Seoul, South-Korea, commented, "EDAP's new Sonolith i-move, with its revolutionary infrared stereo-vision system for stone localization and its modular configurations, really positions the equipment to fully answer current Korean hospital needs. Its innovative features will clearly facilitate the renewal of our strong Sonolith Praktis installed base. Sonolith i-move's superiority is definitively a huge and unique advantage that will allow EDAP to take more market share from the competition, hence strengthening our prominent position in South Korea."

Marc Oczachowski, Chief Executive Officer, added, "The approval of our new Sonolith i-move by the Korean FDA is another step forward in introducing our innovative Sonolith i-move technology in major markets worldwide. It also confirms our capacity to navigate approval processes in various countries to further maintain our leading position in major lithotripsy markets. As we successfully advance in our regulatory milestones, we continue to make progress in view of approval of our Sonolith i-move device by Japanese authorities and US FDA."

The innovative Sonolith i-move is a compact and modular lithotripter with a revolutionary infrared stereo-vision system for real-time, three-dimensional ultrasound free line localization of urinary stones. With its various and flexible configurations, the Sonolith i-move offers a wide range of treatment procedures for clinical sites and hospitals. Its patented and unique electro-conductive technology has proved successful and demonstrated the highest efficiency rates, thus definitely bringing significant benefits to patients and users.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs